文献库搜索 | GeneLibs

ALTamimi(AO),Elemam(NM),Hafezi(S),Saber-Ay... Front Pharmacol None

...PIK3CA, and TP53, on tumor progression and highlight their dynamic interactions with the TME, which can modulate, mask, ...

Zhang(H),Gu(L),Su(X),Chen(W),Tan(M),Yu(H),... Cancer Commun (Lond) None

...PIK3CA), AKT serine/threonine kinase 3 (AKT3), and integrin subunit β1 (ITGB1). Importantly, the enhanced protein transl...

Schmid(P),Ma(CX),Park(YH),Lord(S),Armstron... Clin Cancer Res 2026-08-14

...PIK3CA/AKT1/PTEN alterations, and CD73, with a trend for improved activity in the PD-L1-positive subgroups. These findin...

Veta Darkovski(J),Michelon(I),Gazzoni(G),M... Breast Cancer Res 2026-05-27

...PIK3CA alterations demonstrated a median PFS of 5.3 (3.6-7.4) and 4.7 (3.6-6.7) months, respectively. This meta-analysis...

Ferreira(J),Albergaria(A),Schmitt(F) Cancers (Basel) 2026-05-10

...PIK3CA and ESR1, germline/somatic BRCA1/2, and PD-L1 expression. Furthermore, liquid biopsy, particularly the analysis o...

Adler(ER),Mohammad(A),Kumar(P),Rounbehler(... Cancers (Basel) 2026-05-19

...PIK3CA, are mutated in up to 32%, 15%, and 11% of localized prostate tumors, respectively. We aimed to further character...

Guo(Y),Wang(X),Gao(Y),Xu(Y),Fang(Z),Liu(S)... Biomolecules 2026-05-18

...PIK3CA, AKT, Bax, and Bcl-2, providing supportive in silico evidence for its potential modulation of EGFR/PI3K/AKT signa...

Kawczak(P),Bączek(T) J Clin Med 2026-05-12

...PIK3CA-mutated breast cancer and represents a promising strategy in gynecologic tumors with aberrant PI3K/AKT/mTOR pathw...

Damaskos(C),Garmpis(N),Arkadopoulos(N),Mic... J Clin Med 2026-05-15

...PIK3CA, AKT1, or PTEN alterations. Drug combination approaches with paclitaxel or olaparib have demonstrated additive or...

Tedasen(A),Chatatikun(M),Netphakdee(R),Hua... Life (Basel) 2026-04-23

...PIK3CA-which serve as key regulators in CKD pathophysiology. Gene Ontology and KEGG pathway enrichment analyses indicate...